Pinealon
UnregulatedAlso known as: EDR peptide, Glu-Asp-Arg
Nootropic & NeuroprotectiveLast reviewed: April 28, 2026
A synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology — the same institution behind Epitalon. Pinealon is designed to target the central nervous system and pineal gland, with research focused on neuroprotection, cognitive function, and circadian rhythm regulation.
Mechanism of Action
Penetrates the blood-brain barrier and accumulates in neurons. Modulates gene expression related to neuronal survival and function. Reduces oxidative stress in neural tissue. Appears to regulate melatonin synthesis through pineal gland activity, supporting circadian rhythm normalization.
Common Uses
- Cognitive enhancement and memory
- Neuroprotection
- Sleep quality improvement
- Age-related cognitive decline
- Stroke recovery support (preliminary research)
Known Risks
- Very limited independent Western research
- Most studies from Russian institutions
- Long-term safety unknown
- Mechanism not fully characterized
- Injection site reactions
Regulatory Status
Not FDA-approved and not on any compounding list. Available as a research chemical. Research base is almost entirely from Russian institutions — independent replication is limited. Not affected by the 2026 regulatory changes.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
0.1–0.2 mg/kg body weight
Frequency
Once daily for 10 days (course-based)
Cycle Length
10-day course, 1–2x per year
Often used in short courses alongside Epitalon. Russian clinical protocols use weight-based dosing. Stack with Epitalon for combined anti-aging and neuroprotective effects.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.